HealthyWay Inc (2587) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of HealthyWay Inc HK$1.64, price HK$0.72, upside +129.4%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch HealthyWay Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
21‑month range HK$0.7150 – HK$60.00 · fair‑value band HK$0.9500 – HK$2.05 · the HK$0.7150 price screens below the HK$1.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow HealthyWay in your weekly email
Every Wednesday you see whether HealthyWay is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HealthyWay Inc., an investment holding company, provides corporate and digital marketing, and health and medical services in the People's Republic of China.
Show more
HealthyWay Inc., an investment holding company, provides corporate and digital marketing, and health and medical services in the People's Republic of China. The company offers medical support services for individuals to manage their everyday health and wellness through health membership schemes and other medical support services, including medical consultation services, and supporting services to hospitals. It also involved in the provision of healthcare service packages; and pharmaceutical sales business. In addition, the company offers content services, including wellness content, precision content, and RWS support services; information technology services to corporate and institutional customers; and digital marketing services to advertisers through publishing and posting original marketing articles and brand-building advertisements through platform and other third-party online media channels. Further, the company operates Yihu.com, a health and medical platform. HealthyWay Inc. was founded in 2001 and is headquartered in Fuzhou, the People's Republic of China.
Stock analysis
HealthyWay Inc (2587) currently trades at HK$0.7150, while our model-based Fair Value estimate is HK$1.64, implying the stock looks roughly 56.4% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$3.33 per share, and 22 of the 24 models we run sit above the HK$0.7150 price.
Bear case: the Asset-Based group reads lowest at HK$0.2500, and 2 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.9500 (bear) to HK$2.05 (bull), the price of HK$0.7150 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
HealthyWay Inc reported revenue of 1.6B CNY in FY2025 versus 431M CNY in FY2021, a compound +38.0%/yr. Reported net income was 55.7M CNY in FY2025.
Key figures
Market cap HK$2.1B (≈ $265M) · P/E ratio 34.0 · P/S ratio 1.21 · EPS (TTM) HK$0.0100 · Net margin 3.6% · Return on equity 21.1% · Return on assets (EBIT) −6.9% · Operating margin 4.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 92% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 129%, 2587 screens cheaper than that median.
Fair Value models
Bear HK$0.9500Fair Value HK$1.64Bull HK$2.05
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0075 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+30.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.0%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−16.0% (2021) → 4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +2.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+129.4% · Top 25%
Profitability
Return on equity (TTM)21.1% · Top 25%
Return on assets5.7% · Top 25%
Net margin (TTM)3.6% · Above median
Operating margin (TTM)4.5% · Above median
Growth and dividend
Revenue growth77.3% · Top 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "HealthyWay Inc Fair Value". https://www.fairvalue-calculator.com/stock/2587
Frequently asked questions
Is HealthyWay Inc (2587) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.64 versus a price of HK$0.7150, about +129% upside (undervalued).
What is the fair value of 2587?
Our model-based fair value for HealthyWay Inc is HK$1.64 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.7150.
What is the quality score of 2587?
HealthyWay Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HealthyWay Inc (2587)?
Our model-based price target is the fair value of HK$1.64 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$0.9500, optimistic scenario HK$2.05. It is a calculation from audited fundamentals, not an analyst target.
What is the HealthyWay Inc stock forecast for 2026?
Our models put fair value at HK$1.64, about +129% upside versus a price of HK$0.7150 (undervalued). Cautious scenario HK$0.9500, optimistic scenario HK$2.05. The calculation is refreshed regularly with new filings.
What is the revenue of HealthyWay Inc (2587)?
HealthyWay Inc reported trailing-twelve-month revenue of about 1.6B CNY (latest available figure, as of Sep 27, 2026).
What growth is priced into HealthyWay Inc (2587)?
For today's price to be fair in a discounted-cash-flow model, HealthyWay Inc would have to grow free cash flow by +3.8 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +38.0 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 2587 use?
Our models discount HealthyWay Inc at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HealthyWay Inc that is +3.8 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has HealthyWay Inc (2587) delivered so far?
Over the past 4 years revenue at HealthyWay Inc grew +38.0 % a year. The price currently implies +3.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HealthyWay Inc (2587) growing?
The median revenue growth in the sector is +4.4 % a year. That is the yardstick for the growth priced into HealthyWay Inc (+3.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HealthyWay Inc (2587)?
The free-cash-flow yield on the price is 7.50 %: that much free cash flow HealthyWay Inc produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HealthyWay Inc (2587)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HealthyWay Inc it is HK$1.64 per share (as of Sep 27, 2026), against a price of HK$0.7150. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is HealthyWay Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2587 trades below its calculated fair value: price HK$0.7150, fair value HK$1.64, a gap of about +129% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2587?
No. The price is what the market pays today (HK$0.7150); the fair value is what the company's own numbers justify (HK$1.64). For HealthyWay Inc the two are HK$0.9250 per share apart. That gap is exactly why we show both numbers side by side.
How much is HealthyWay Inc worth?
The market values HealthyWay Inc at about HK$2.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.7150; our models calculate a fair value of HK$1.64 per share.
What do the bullish and bearish scenarios say about 2587?
Our models span a range for HealthyWay Inc: cautious scenario HK$0.9500, base HK$1.64, optimistic HK$2.05 per share (as of Sep 27, 2026, price HK$0.7150). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2587?
HealthyWay Inc trades at a price-to-earnings ratio of 34.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.64 is built from several models across several years. Other multiples: P/B 6.4, P/S 1.1, EV/EBITDA 14.9.
How solid is the balance sheet of HealthyWay Inc (2587)?
Balance-sheet figures for HealthyWay Inc (as of Sep 27, 2026): return on equity 21.1%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 2587 from its 52-week high?
HealthyWay Inc trades at HK$0.7150, about 92% below its 52-week high of HK$8.43 and at the low of HK$0.7150 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.64 is for.
Which stocks are comparable to HealthyWay Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HealthyWay Inc stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.7150, calculated fair value HK$1.64 (+129%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2587 calculated?
We run HealthyWay Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. HealthyWay Inc currently trades 56 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HealthyWay Inc (2587)?
The closing price on Sep 30, 2026 was HK$0.7150. Our model-based fair value is HK$1.64, about +129% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HealthyWay Inc right now?
The price is below even our cautious bear case (HK$0.9500). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$0.9500 to HK$2.05) leaves room in how you read the outcome.
Key figures of HealthyWay Inc
How large is the market capitalisation of HealthyWay Inc (2587)?
The market capitalisation of HealthyWay Inc is HK$2.1B (≈ $265M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HealthyWay Inc (2587)?
The price-to-sales ratio of HealthyWay Inc is 1.21 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HealthyWay Inc (2587)?
Earnings per share at HealthyWay Inc are HK$0.0100 (price ÷ EPS = P/E 34.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HealthyWay Inc (2587)?
The net margin of HealthyWay Inc is 3.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HealthyWay Inc (2587)?
The return on equity (ROE) of HealthyWay Inc is 21.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HealthyWay Inc (2587)?
On an EBIT basis the return on assets of HealthyWay Inc is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HealthyWay Inc (2587)?
The operating margin of HealthyWay Inc is 4.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HealthyWay Inc (2587)?
Revenue at HealthyWay Inc is growing +77.3% versus a year earlier (3y avg +40.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch HealthyWay Inc in the live analysis
One click puts HealthyWay Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
